Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 12Nausea 12Neoplasms 8Hematologic Neoplasms 5Anorexia 4Cachexia 3Breast Neoplasms 3Weight Loss 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Lung Neoplasms 2Advanced Cancer 2Testicular Neoplasms 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Sedentary Behavior 1Radiation Injuries 1Prosthesis Failure 1Postoperative Nausea and Vomiting 1Pain 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Muscular Atrophy 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1

Interventions

Dexamethasone 5ramosetron 3Ondansetron 2Calcium Dobesilate 2Acupuncture Therapy 2phenazine 1esmolol 1Therapeutics 1Surveys and Questionnaires 1Sufentanil 1Promethazine 1Postoperative Care 1Olanzapine 1Gelatin 1Fentanyl 1Famotidine 1Electroacupuncture 1Electric Stimulation Therapy 1Electric Stimulation 1Diphenhydramine 1Dexmedetomidine 1Aprepitant 1Antiemetics 1Anesthesia, General 1Anesthesia 1Adrenergic beta-Antagonists 1((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Postoperative Nausea and Vomiting × Olanzapine × Clear all
NCT03631004 2022-01-13

Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

Instituto do Cancer do Estado de São Paulo

Phase 2/3 Completed
100 enrolled

Nausea, Vomiting, Postoperative Nausea and Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡